2017 American Society of Clinical Oncology Annual Meeting*

Momelotinib achieved noninferior spleen response vs rituximab, with inferior total symptom response rate.

Results from this phase III study reveal comparable splenic response rate but improved symptomatic response and transfusion independence rates with momelotinib vs BAT.

Study investigators conclude that molecular response may predict durable clinical benefit in patients treated with gilteritinib.

Enasidenib was associated with durable CRs and low rates of treatment-related grade 3/4 adverse events.

Results of 19-28z CAR T-cell treatment in patients with R/R B-cell ALL suggest higher CR rate, extended survival, and reduced toxicity in patients with baseline minimal vs morphologic disease burden.

BR associated with significantly increased 5-year PFS, duration of response, and event-free survival vs R-CHOP/R-CVP in overall patient population, particularly in MCL subgroup.

Rituximab plus lenalidomide showed activity, tolerable safety in patients with R/R follicular lymphoma, including those with double-refractory disease or early relapse on prior therapy.

The addition of ublituximab to ibrutinib improved ORR vs ibrutinib alone with a similar safety profile except for an increase in ublituximab-related infusion reactions.

Results from this interim analysis suggest no benefit to radiotherapy in elderly DLBCL patients who are PET negative for bulky disease after immunochemotherapy.

Daratumumab addition to standard therapy was associated with an ORR of 100% after median follow-up of 10.8 months.

Addition of elotuzumab to RVD associated with high level of overall response in newly diagnosed patients with MM but higher than expected toxicity.

KCd use was associated with a lower rate of nonhematologic AEs and improved odds for PBSC mobilization vs KRd use.

Results of this large international phase III trial showed that denosumab was associated with significantly less renal toxicity and prolonged PFS vs zoledronic acid in patients with newly diagnosed MM.

Phase I results suggest isatuximab-based combination safe, clinically active in highly treatment-experienced R/R MM.

In this expert analysis, Sagar Lonial, MD; John M. Burke, MD; and Farhad Ravandi, MD, review key data from the most clinically relevant studies on the management of hematologic malignancies presented at the 2017 Clinical Oncology annual meeting in Chicago.

John M. Burke, MD Sagar Lonial, MD Farhad Ravandi, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits™ Released: August 18, 2017 Expired: No longer available for credit